P. Kent Hawryluk Acquires 50,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX) CEO P. Kent Hawryluk purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was purchased at an average price of $10.69 per share, for a total transaction of $534,500.00. Following the transaction, the chief executive officer now directly owns 448,277 shares in the company, valued at approximately $4,792,081.13. This trade represents a 12.55 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

MBX Biosciences Stock Up 2.9 %

Shares of NYSE MBX opened at $11.25 on Thursday. MBX Biosciences, Inc. has a twelve month low of $9.42 and a twelve month high of $27.50. The business’s fifty day moving average price is $16.47.

MBX Biosciences (NYSE:MBX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($2.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.06). On average, research analysts predict that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

Institutional Investors Weigh In On MBX Biosciences

Several large investors have recently added to or reduced their stakes in MBX. Rhumbline Advisers acquired a new position in shares of MBX Biosciences during the fourth quarter valued at about $175,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $278,000. Point72 Asset Management L.P. bought a new position in MBX Biosciences in the third quarter worth approximately $405,000. Barclays PLC acquired a new stake in MBX Biosciences in the third quarter valued at approximately $426,000. Finally, Geode Capital Management LLC bought a new stake in shares of MBX Biosciences during the third quarter valued at approximately $579,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.